Allergic Rhinoconjunctivitis Clinical Trial
Official title:
Evaluation of Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts as an Adjuvant
The purpose of this study is to determine the changes of quality of life of patients with allergic rhinoconjunctivitis treated with standard medications plus Dialyzable Leukocyte Extracts (DLE). All patients will receive DLE in combination with current guide lines-suggested standard medication.
DLE are heterogenous mixtures of peptides under 10 kilo Daltons (kDa) obtained after
disruption of peripheral blood leukocytes from healthy human donors. DLE have been reported
to improve clinical response in allergies, such as asthma and atopic dermatitis.
The therapeutic effect of DLE is related to an immune modulatory effect that changes innate
signaling pathways, such as Toll Like Receptors, and Nuclear Factor -kappa B; production of
cytokines might also be modified with the use of DLE, including Tumor Necrosis Factor a,
Interleukin (IL)-6, and induction of Interferon-g secretion, driving immune response to a
T-helper Th1 immune-regulatory response, and thus helping to reduce allergy symptoms.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
| Completed |
NCT03682965 -
Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study
|
Phase 2 | |
| Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
| Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
| Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
| Completed |
NCT01966224 -
A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects
|
Phase 1 | |
| Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
| Completed |
NCT01438827 -
Avanz Phleum Pratense Maintenance Dose
|
Phase 2/Phase 3 | |
| Completed |
NCT01438463 -
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 2 | |
| Completed |
NCT02437786 -
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®
|
Phase 4 | |
| Completed |
NCT00985296 -
Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)
|
N/A | |
| Completed |
NCT01740284 -
A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine
|
Phase 3 | |
| Completed |
NCT04912076 -
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
|
Phase 1 | |
| Completed |
NCT03365648 -
Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics
|
N/A | |
| Completed |
NCT05455749 -
Effect of holoBLG on Cat Allergic Patients
|
N/A | |
| Completed |
NCT01707069 -
A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid
|
Phase 1 | |
| Completed |
NCT01567306 -
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
|
Phase 2 | |
| Completed |
NCT01466465 -
Vitamin D and Grass Pollen Specific Immunotherapy
|
Phase 2 | |
| Completed |
NCT01490411 -
Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis
|
Phase 2 | |
| Completed |
NCT00777374 -
Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration
|
Phase 2 |